Living mapping and living systematic review of Covid-19 studies
Randomized Trials (excluding Traditional Chinese Medicine trials)
690 RCTs recruiting
Randomized Controlled Trials
On July 3 we have screened 280 new records.
Several randomized trials were identified this week assessing the effect of Dexamethasone, Colchicine, Hydroxychloroquine, and Chloroquine in addition to a trial evaluating re-Opening of Training Facilities during the COVID-19 pandemic are available on our website. Observational studies assessing Ivermectine, Hydroxychlroquine, Methylprednisolone, steroids and Immunoglobulin are available as well. Risk of bias assessments of all included and analysed studies are published on our website.
Following the publication of an expression of concern by the Lancet (June 3, 2020) regarding the paper by Mandeep Mehra et al—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, and the retraction by 3 of the authors (June 4, 2020), we decided to delete data related to this study from our website
The research mapping has been updated on June 23, 2020 with 49 new registered RCTs identified in the WHO ICTRP.
To receive updates on our project and research findings, please subscribe to our weekly digest, we will share with you new RCT results and other interesting news.
Our main activities
We are performing a living mapping of ongoing research followed by a living network meta-analysis of study results as soon as they are available.
- We are searching and extracting data from RCTs registered in ICTRP once a week (the WHO updates its registry every Wednesday)
- A living mapping of studies registered is now available: it is possible to filter studies by type of pharmacological treatment, registration date, study aim, severity scale. An interactive map showing the clinical trials per country is also available. This data visualization was developed by a team from the LIRIS laboratory (CNRS/École Centrale de Lyon) in the context of a large collaboration with the CNRS. Several other teams from CNRS have offered their help for this project to contribute to the fight against Covid-19. As a result, more graphs and tables are currently being developed and will be soon available on our website.
- We are screening electronic databases (PubMed/Chinarxiv and MedRxiv) every day to identify results of RCTs and non-randomized-studies and case series.
- We are collecting data from all RCTs identified. The main characteristics of trials, including a complete description of the assessment of each risk of bias domain with support for judgement and forest plots are available here. The Evidence profile and Summary of Findings (SoF) tables for most of the comparisons are also available online and the missing ones are currently being designed.
- We are contacting all investigators of ongoing trials to obtain the trial protocol and results as soon as available.
- Several databases of the reference list for modeling studies, observational studies, RCTs and non-RCT studies and studies we excluded from our systematic review are available online . Users of datasets published by the Covid-NMA project are required to acknowledge the source with an appropriate citation. We recommend using the following format: Authors. (Year). Dataset title [Data set]. Repository. DOI
This study receives some funding from a grant from the ANR (Agence Nationale de la Recherche).